GlaxoSmithKline S.A.E (EGX:BIOC)

GlaxoSmithKline S.A.E Statistics

Total Valuation

EGX:BIOC has a market cap or net worth of EGP 3.26 billion. The enterprise value is 3.30 billion.

Market Cap	3.26B
Enterprise Value	3.30B

Important Dates

The next estimated earnings date is Monday, May 19, 2025.

Earnings Date	May 19, 2025
Ex-Dividend Date	Jul 18, 2024

Share Statistics

EGX:BIOC has 83.51 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	83.51M
Shares Change (YoY)	n/a
Shares Change (QoQ)	+0.68%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	2.43M

Valuation Ratios

The trailing PE ratio is 18.72.

PE Ratio	18.72
Forward PE	n/a
PS Ratio	1.09
PB Ratio	1.63
P/TBV Ratio	1.63
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 6.88, with an EV/FCF ratio of -6.25.

EV / Earnings	18.98
EV / Sales	1.10
EV / EBITDA	6.88
EV / EBIT	7.73
EV / FCF	-6.25

Financial Position

The company has a current ratio of 1.82, with a Debt / Equity ratio of 0.06.

Current Ratio	1.82
Quick Ratio	0.47
Debt / Equity	0.06
Debt / EBITDA	0.25
Debt / FCF	-0.23
Interest Coverage	40.17

Financial Efficiency

Return on equity (ROE) is 8.78% and return on invested capital (ROIC) is 12.74%.

Return on Equity (ROE)	8.78%
Return on Assets (ROA)	7.38%
Return on Invested Capital (ROIC)	12.74%
Return on Capital Employed (ROCE)	20.51%
Revenue Per Employee	3.74M
Profits Per Employee	217,475
Employee Count	800
Asset Turnover	0.83
Inventory Turnover	2.51

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +22.55% in the last 52 weeks. The beta is 0.95, so EGX:BIOC's price volatility has been similar to the market average.

Beta (5Y)	0.95
52-Week Price Change	+22.55%
50-Day Moving Average	38.16
200-Day Moving Average	35.68
Relative Strength Index (RSI)	59.04
Average Volume (20 Days)	51,433

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, EGX:BIOC had revenue of EGP 2.99 billion and earned 173.98 million in profits. Earnings per share was 2.08.

Revenue	2.99B
Gross Profit	933.94M
Operating Income	425.87M
Pretax Income	338.72M
Net Income	173.98M
EBITDA	465.79M
EBIT	425.87M
Earnings Per Share (EPS)	2.08

Balance Sheet

The company has 75.47 million in cash and 119.48 million in debt, giving a net cash position of -44.01 million or -0.53 per share.

Cash & Cash Equivalents	75.47M
Total Debt	119.48M
Net Cash	-44.01M
Net Cash Per Share	-0.53
Equity (Book Value)	2.00B
Book Value Per Share	23.89
Working Capital	1.29B

Cash Flow

In the last 12 months, operating cash flow was -404.15 million and capital expenditures -124.34 million, giving a free cash flow of -528.49 million.

Operating Cash Flow	-404.15M
Capital Expenditures	-124.34M
Free Cash Flow	-528.49M
FCF Per Share	-6.33

Margins

Gross margin is 31.23%, with operating and profit margins of 14.24% and 5.82%.

Gross Margin	31.23%
Operating Margin	14.24%
Pretax Margin	11.33%
Profit Margin	5.82%
EBITDA Margin	15.57%
EBIT Margin	14.24%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 0.75, which amounts to a dividend yield of 1.90%.

Dividend Per Share	0.75
Dividend Yield	1.90%
Dividend Growth (YoY)	-80.00%
Years of Dividend Growth	n/a
Payout Ratio	40.05%
Buyback Yield	n/a
Shareholder Yield	1.90%
Earnings Yield	5.34%
FCF Yield	-16.23%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

EGX:BIOC has an Altman Z-Score of 3.11.

Altman Z-Score	3.11
Piotroski F-Score	n/a